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Abstract
BRCA and poly-ADP ribose polymerase (PARP) regulate pathways of DNA repair. Due to the
accumulation of mutations introduced by error-prone DNA repair, breast and ovarian cancers
develop in the setting of BRCA deficiency. A series of recent clinical trials has tested the use of PARP
inhibition as a therapeutic strategy to target BRCA-deficient tumors.
Introduction and context
DNA sustains damage through exposure to chemicals, UV
light, ionizing radiation, chemotherapy, or products of
cellular metabolism [1]. Damaged DNA triggers cell cycle
arrest and transcriptional activation. Single-strand breaks
are faithfully repaired through base excision, nucleotide
excision, or mismatch repair. Double-strand breaks are
repaired by homologous recombination (HR), a process
that restores the original genetic sequence, or by non-
homologous end joining or single-strand annealing,
processes that lack fidelity to the germline DNA sequence.
Use of DNA repair pathways that are prone to error
generates a new erroneous sequence. Malignancy arises
when DNA is repaired with errors causing mutations that
activate oncogenes or knock out tumor suppressor genes.
If DNA is damaged to such an extent that it cannot be
repaired by any mechanism, then cells cannot transcribe
genes or replicate chromosomes, and will die.
The BRCA1 gene was identified in 1990 as a cause of
hereditary breast cancer and was sequenced in 1994 and
has since been shown to function in the complex HR
pathway of DNA repair [2]. Women carrying a hetero-
zygous deleterious mutation in the BRCA1 gene carry a
57% cumulative risk of developing breast cancer by the
age of 70 years and a 40% risk of developing ovarian
cancer [3]. In the case of a deleterious BRCA2 mutation,
women have a 49% risk of developing breast cancer and
an 18% risk of developing ovarian cancer by age 70.
Tumors that arise in BRCA mutation carriers have lost the
wild-type allele of the BRCA gene and express only the
mutated/truncated allele. Therefore, the tumor cells are
unable to repair DNA through BRCA-dependent
mechanisms.
BRCA1 and BRCA2 regulate repair of damaged DNA
through HR [2]. Active BRCA1 promotes cell cycle arrest
in conjunction with p53 and associates with DNA
double-strand breaks marked by RAD51 foci. ATM
(ataxia telangiectasia mutated) and BRCA2 accumulate
with BRCA1 and RAD51 at the sites of double-strand
DNA damage. RAD51 promotes association with the
sister chromatid, and DNA polymerase proceeds using
the sister chromatid as the template for repair.
In cells lacking functional BRCA1 or BRCA2, HR is
deficient. DNA repair proceeds through more error-prone
repair pathways. Repair triggered in this manner typically
removes the region of damaged DNA and joins the
truncated DNA fragment with intact DNA. The cell cycle
then resumes, propagating the deletion-mutated
sequence. Chromosome instability in the BRCA-mutated
HR-deficient cells thus perpetuates cellular proliferation
in the setting of potential oncogene activation. It is
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susceptible to the oncogenic outcome of BRCA deficiency.
HR-deficient cells are exquisitely sensitive to inhibition
of PARP (poly-ADP ribose polymerase 1 and 2) [4].
PARP is activated by DNA damage and subsequently
modifies histones and DNA-associated proteins by ADP
ribosylation.Areas of single-strandDNA damage are thus
marked and signal the assembly of DNA repair com-
plexes, primarily in the base excision repair pathway.
With continuous PARP inhibition, single-strand breaks
are converted to double-strand breaks at replication
forks, which predominantly depend on HR. The accu-
mulation of double-strand breaks overwhelms the DNA
repair mechanisms in HR-deficient cells. Irreparable
DNA damage triggers cell death (Figure 1). Therefore,
inhibiting PARP has been undertaken as a strategy to
selectively kill cells with dysfunctional BRCA proteins.
Major recent advances
PARP inhibitors in clinical development
Small-molecule inhibitors of PARP activity began devel-
opment as sensitizers to DNA-damaging chemotherapy
or ionizing radiation. Due to the intrinsic synthetic
lethality of the underlying defect in BRCA-dependent
DNA repair, BRCA-deficient cancer cells are 1000-fold
more sensitive to single-agent PARP inhibition. The
concept of synthetic lethality – in which functional
inhibition of two proteins leads to cell death but
blockade of either alone does not – is well illustrated
by the use of PARP inhibitors in BRCA-deficient cancers.
If eitherPARP or BRCA function remains intact, a cell will
continue to survive. Therefore, inhibiting PARP should
not affect the non-cancerous cells that contain one
functional copy of BRCA. Loss of both functions,
however, is incompatible with life [5,6]. Preclinical
studies supported this concept in vitro and in mouse
models of BRCA-deficient tumors, thus prompting the
clinical development of PARP inhibitors for these genetic
cohorts of patients [4].
Six highly potent and specific PARP inhibitors are
currently in clinical development in oncology [7]. BSI
201 (BiPar Sciences Inc., South San Francisco, CA, USA)
hasenteredaphaseIIItrialfortriple-negativebreastcancer
in combination with gemcitabine and carboplatin (G/C).
Three agents– olaparib (AZD 2281;AstraZeneca, London,
UK), ABT888 (AbbottLaboratories, AbbottPark, IL, USA),
and AG014966 (Pfizer Inc., New York, NY, USA) – are
inphaseIIclinicaltrialsassingle agents orincombination
with chemotherapy. Two PARP inhibitors are in phase I
trials: MK4827 (Merck, Darmstadt, Germany) and
Figure 1. Mechanism of sensitivity to PARP inhibition in BRCA-deficient cells
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Cells acquire DNA damage through environmental exposures or chemotherapy agents. Repair of single-strand breaks relies on PARP; repair of double-strand
breaks depends on BRCA. With PARP inhibition, single-strand breaks progress to double-strand breaks. In the absence of functional BRCA, the accumulation
of double-strand breaks overwhelms DNA repair mechanisms. Irreparable DNA damage triggers cell death. DSB, double-strand break; NHEJ,
non-homologous end joining; PARP, poly-ADP ribose polymerase; SSA, single-strand annealing; SSB, single-strand break.
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tional agents entered clinical development but have not
been pursued: GPI 21016 (Sanofi-Aventis, Paris, France)
and INO-1001 (Genentech, Inc., South San Francisco,
CA, USA).
PARP inhibitors in BRCA-deficient cancer
A recent phase I clinical trial identified the maximum
tolerated dose of olaparib in patients with solid tumors
and evaluated activity in an expansion cohort of
20 patients with BRCA-deficient tumors [8]. Of the
19 patients evaluable, 12 (63%) showed evidence of
clinical benefit as defined by objective response (radio-
graphic or tumor marker) or stabilization of disease for 4
months or longer. These results prompted phase II trials
to extend the evaluation of efficacy specifically in BRCA-
deficient ovarian cancer or breast cancer.
Early results of these phase II trials were presented at the
American Society of Clinical Oncology (ASCO) 2009
Annual Meeting. The phase II trial of the PARP inhibitor
olaparib in BRCA-deficient advanced breast cancer
accrued two sequential cohorts of patients [9]. The first
27 patients received olaparib at 400 mg twice daily, and
the second 27 patients received olaparib 100 mg twice
daily since the pharmacodynamic results from the phase
I trial showed maximal PARP inhibition in peripheral
blood cells at the 100 mg dose. The therapy was well
tolerated, and investigators reported a 41% overall
response rate in the patients of the first cohort, with a
median progression-free survival of 5.7 months. The
second clinical trial tested the same two sequential dose
cohorts in women with BRCA-deficient advanced ovar-
ian cancer [10]. At the time of the preliminary report,
33 patients were treated at the 400 mg dose, with
response in 57.6% of patients and a median progression-
free survival of 5.8 months. Of 24 other patients treated
at the 100 mg dose, 16.7% had achieved a response, with
a progression-free survival of 1.9 months. Although not
statistically powered to evaluate differences between the
two dose cohorts, these preliminary results suggest that
the pharmacodynamic saturation of PARP inhibition, as
tested in peripheral blood cells of the patients in the
phase I trial, may not have adequately reflected the level
of activity of this compound in the tumors.
Triple-negative breast cancer – lacking expression of
estrogen receptor (ER), progesterone receptor, and
HER2 – is an aggressive breast cancer subtype that shares
molecular and pathologic features with BRCA1-related
breast cancers. The majority of BRCA1-deficient breast
cancers occur as the triple-negative phenotype. Recent
molecular evidence suggests a necessity for functional
BRCA1 protein in inducing expression of ER in breast cell
progenitors [11,12]. Sporadic triple-negative breast cancer
occurring in non-mutation carriers may similarly result
from epigenetic silencing of BRCA1 and ER by aberrant
methylationofthese genes’ promoters [13].A randomized
phase II trial, also presented at the ASCO 2009 Annual
Meeting, evaluated the efficacy of G/C with or without the
PARP inhibitor BSI-201 [14]. Patients were randomly
assigned to G/C alone or G/C + BSI-201. Endpoints were
clinical benefit rate (CBR) (that is, complete response +
partial response + stable disease of at least 6 months),
progression-free survival, andoverall survival. Early results
ofthis trial showed that BSI-201improved CBR from 21%
to 62% (P = 0.0002), increased progression-free survival
from 3.3 to 6.9 months (P <0.0001), and extended overall
survival from 5.7 to 9.2 months (P = 0.0005) in these
patients.
Future directions
In summary, these trials have provided proof of principle
in achieving synthetic lethality of PARP inhibition in the
setting of BRCA deficiency in human cancer. BRCA-
deficient cancers typically show heightened sensitivity to
DNA-damaging chemotherapeutic agents that cause
double-strand breaks in DNA typically repaired by HR
[2]. Ongoing clinical trials at the National Cancer Institute
and elsewhere are testing the safety and efficacy of using
PARP inhibitors in combination with chemotherapeutic
agents that induce double-strand breaks, such as carbo-
platin, topotecan, cyclophosphamide, or temozolomide,
in patients carrying BRCA1 or BRCA2 germline mutations.
It has been postulated that the combination of a PARP
inhibitor with a DNA-damaging agent may lead to
excessive myelosupression. Our general impression thus
far, however, is that tolerance of the combined regimen is
more closely related to prior platinum therapy rather than
the existence of the germline mutation. Ongoing studies
will address this question in parallel cohorts. Results of
these trials are eagerly awaited in hopes of improving
response rate and duration and eliminating these
hereditary cancers.
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